No Picture
News

Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma

Proposed NRG-BN006 Phase 2/3 trial to begin enrollment in 2019

SAN DIEGO, Nov. 29, 2018 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Instit… […]

No Picture
News

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

SAN DIEGO, Nov. 28, 2018 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, presented data at the World ADC Summit in San Diego this month descri… […]